Search research articles
Contact Us
Filters
Showing results (231-240 of 266) with videos related to
Page
of 27
Sort By:
Breast Cancer Research and Treatment
|
September 16, 2017
Exome array analysis identifies ETFB as a novel susceptibility gene for anthracycline-induced cardiotoxicity in cancer patients
Sara Ruiz-Pinto, Guillermo Pita, Miguel Martín, et al.
Cardiovascular Revascularization Medicine : Including Molecular Interventions
|
March 30, 2023
Comprehensive Assessment of Myocardial Ischemia Mechanisms in the Catheterization Laboratory: Design and Rationale of the Advanced Invasive Diagnosis Strategy for Patients with Stable Coronary Syndromes Undergoing Coronary ANGIOgraphy - the AID-ANGIO Study
Adrian Jeronimo, Alejandro Travieso, José G Paredes-Vázquez, et al.
The Journal of Dermatological Treatment
|
June 11, 2026
Roflumilast foam versus vehicle foam for seborrheic dermatitis (STRATUM clinical study): a plain language summary
Andrew Blauvelt, Zoe D Draelos, Linda Stein Gold, et al.
JAMA Dermatology
|
May 7, 2025
Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body: The ARRECTOR Phase 3 Randomized Clinical Trial
Melinda J Gooderham, Javier Alonso-Llamazares, Jerry Bagel, et al.
International Journal of Molecular Sciences
|
August 26, 2022
Differences in Expression of <i>IQSEC2</i> Transcript Isoforms in Male and Female Cases with Loss of Function Variants and Neurodevelopmental Disorder
Beatriz Baladron, Lidia M Mielu, Estrella López-Martín, et al.
The British Journal of Dermatology
|
June 6, 2023
Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study
Leon H Kircik, Javier Alonso-Llamazares, Neal Bhatia, et al.
International Journal of Molecular Sciences
|
August 12, 2022
Endoglin and MMP14 Contribute to Ewing Sarcoma Spreading by Modulation of Cell-Matrix Interactions
Pilar Puerto-Camacho, Juan Díaz-Martín, Joaquín Olmedo-Pelayo, et al.
Oncogene
|
July 28, 2025
EWS::FLI1-DHX9 interaction promotes Ewing sarcoma sensitivity to DNA topoisomerase 1 poisons by altering R-loop metabolism
Joaquin Olmedo-Pelayo, Esperanza Granado-Calle, Daniel Delgado-Bellido, et al.
Journal of the American Academy of Dermatology
|
January 22, 2024
Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial
Andrew Blauvelt, Zoe D Draelos, Linda Stein Gold, et al.
Journal of the American Academy of Dermatology
|
March 31, 2024
Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trial
Linda Stein Gold, David N Adam, Lorne Albrecht, et al.
Page
of 27
Search research articles
Search
Showing results (231-240 of 266) with videos related to
Sort By:
Page
of 27
Breast Cancer Research and Treatment
|
September 16, 2017
Exome array analysis identifies ETFB as a novel susceptibility gene for anthracycline-induced cardiotoxicity in cancer patients
Sara Ruiz-Pinto, Guillermo Pita, Miguel Martín, et al.
Cardiovascular Revascularization Medicine : Including Molecular Interventions
|
March 30, 2023
Comprehensive Assessment of Myocardial Ischemia Mechanisms in the Catheterization Laboratory: Design and Rationale of the Advanced Invasive Diagnosis Strategy for Patients with Stable Coronary Syndromes Undergoing Coronary ANGIOgraphy - the AID-ANGIO Study
Adrian Jeronimo, Alejandro Travieso, José G Paredes-Vázquez, et al.
The Journal of Dermatological Treatment
|
June 11, 2026
Roflumilast foam versus vehicle foam for seborrheic dermatitis (STRATUM clinical study): a plain language summary
Andrew Blauvelt, Zoe D Draelos, Linda Stein Gold, et al.
JAMA Dermatology
|
May 7, 2025
Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body: The ARRECTOR Phase 3 Randomized Clinical Trial
Melinda J Gooderham, Javier Alonso-Llamazares, Jerry Bagel, et al.
International Journal of Molecular Sciences
|
August 26, 2022
Differences in Expression of <i>IQSEC2</i> Transcript Isoforms in Male and Female Cases with Loss of Function Variants and Neurodevelopmental Disorder
Beatriz Baladron, Lidia M Mielu, Estrella López-Martín, et al.
The British Journal of Dermatology
|
June 6, 2023
Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study
Leon H Kircik, Javier Alonso-Llamazares, Neal Bhatia, et al.
International Journal of Molecular Sciences
|
August 12, 2022
Endoglin and MMP14 Contribute to Ewing Sarcoma Spreading by Modulation of Cell-Matrix Interactions
Pilar Puerto-Camacho, Juan Díaz-Martín, Joaquín Olmedo-Pelayo, et al.
Oncogene
|
July 28, 2025
EWS::FLI1-DHX9 interaction promotes Ewing sarcoma sensitivity to DNA topoisomerase 1 poisons by altering R-loop metabolism
Joaquin Olmedo-Pelayo, Esperanza Granado-Calle, Daniel Delgado-Bellido, et al.
Journal of the American Academy of Dermatology
|
January 22, 2024
Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial
Andrew Blauvelt, Zoe D Draelos, Linda Stein Gold, et al.
Journal of the American Academy of Dermatology
|
March 31, 2024
Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trial
Linda Stein Gold, David N Adam, Lorne Albrecht, et al.
Page
of 27